SB 1605 amends Missouri’s controlled substances scheduling statute, section 195.017, RSMo, by revising the state’s Schedule I list and specifically adding 7-hydroxymitragynine when it is concentrated above 400 parts per million on a dry-weight basis. The bill’s caption and text indicate that its primary purpose is to classify that substance as a Schedule I controlled substance, meaning it would be treated as having a high potential for abuse and no accepted medical use under Missouri law.
Although the bill is focused on 7-hydroxymitragynine, it also republishes the state’s controlled substances schedules in full, including extensive lists of opioids, fentanyl-related substances, hallucinogens, stimulants, depressants, anabolic steroids, and other regulated drugs. The bill leaves in place the existing framework for how the Department of Health and Senior Services classifies substances into Schedules I through V, and it preserves related rules for pseudoephedrine/ephedrine sales, pharmacy logging, reporting, exemptions, and annual republication of the schedules.
The practical impact would be to make possession, distribution, manufacture, and other regulated handling of high-concentration 7-hydroxymitragynine subject to Missouri’s Schedule I controlled substance laws, with corresponding criminal and regulatory consequences under the state’s controlled substances chapter. It would affect individuals and businesses dealing in kratom-derived products or other preparations containing that compound, while leaving lower-concentration or otherwise exempted products outside the new Schedule I listing as written.
The available context shows no recorded committee transcript, no vote history, and no formal action data, so there is no documented debate to gauge legislative sentiment from the provided materials. Based on the bill text and caption alone, the measure appears to reflect a public-safety and drug-control approach aimed at restricting a specific opioid-like compound rather than broadening drug policy generally.
Because there are no transcripts, the main point of contention is inferred rather than documented: the likely issue is whether 7-hydroxymitragynine should be treated as a dangerous Schedule I substance, especially given its relationship to kratom products and possible arguments about medicinal use, consumer access, and the appropriate concentration threshold. Any opposition would likely center on overbreadth, impacts on kratom users and retailers, and whether a concentration-based ban is the right regulatory tool.
SB 1605 would amend section 195.017, RSMo, the state statute governing controlled substance schedules, by adding 7-hydroxymitragynine above a specified concentration to Schedule I. This would place the substance within Missouri’s most restrictive controlled-substance category and subject it to the legal consequences associated with Schedule I drugs under state law. The bill does not otherwise restructure the scheduling system, but it does update the statutory list of controlled substances and thereby affects enforcement, prosecution, and regulatory treatment of products containing the substance.
The provided record contains no committee discussion or roll-call votes, so there is no direct evidence of bipartisan support or opposition in the materials. The bill’s framing suggests a law-enforcement and public-health oriented intent, and the caption indicates a straightforward scheduling measure rather than a broader policy compromise. On that basis, the apparent sentiment is neutral-to-supportive in the text itself, but the absence of recorded debate means the level of legislative consensus cannot be determined from the supplied context.
No specific objections are documented in the supplied transcripts or vote history, but the likely area of contention is the treatment of 7-hydroxymitragynine as Schedule I, particularly because the substance is associated with kratom products and may be argued by some to have medicinal or consumer-use implications. Potential opponents would likely focus on the concentration threshold, the effect on lawful retail products, and whether the bill could sweep in products that are not being used for illicit purposes. Supporters would likely emphasize abuse potential, opioid-like effects, and the need for clearer state control.